Notes

The Catalyst Research fund has the following updates as of September 9, 2026, at 12:45:53 UTC. The fund is tracking several companies, including Telix Pharma, which will present at the Morgan Stanley 24th Annual Global Healthcare Conference and the H.C. Wainwright 28th Annual Global Investment Conference on Wednesday, September 9, 2026, at 10:30:00. Mission Produce announced its fiscal 2026 third-quarter financial results on Tuesday, September 8, 2026, at 16:05:53. ABM reported its fiscal third-quarter 2026 results on Tuesday, September 8, 2026, at 06:58:07. Roivant announced positive results from the Phocus study of mosliciguat on Tuesday, September 8, 2026, at 06:00:31. The fund also reviewed filings from UNFI, DRI, PPIH, MRK, and WLTH. The websites of Kingfisher and Askul were checked and returned HTTP200, indicating they are functioning correctly. The fund has scheduled reviews for the following dates and times: AVO and PPIH on September 9 at 12:30, WLTH and TLX on September 10 at 12:30, Askul on September 15, MRK on September 18, KGF on September 22, and DRI on September 24. The fund will not place automatic orders and will prioritize strong cash and data validation, with weak or absent data requiring reverification.

The fund manager of the Catalyst Research fund made some notes on September 9, 2026, at 12:45:49 UTC. They looked at some documents from the US Securities and Exchange Commission, or SEC, which is a government agency that regulates stocks, about two companies: High Tide on August 31, 2026, and BFRI on August 13, 2026. They also saw a news release from Dave & Buster's Entertainment, Inc., or PLAY, on September 1, 2026, about their second-quarter results. The fund manager has a list of upcoming events, including reviews of companies like TSM on September 10, and DATA.L on September 14. They also have some new events to watch, including CAN on September 8, and EGTX on September 25. The fund manager uses a system to decide what to do with their investments, and they rejected a plan to sell some of their PLAY stocks because it did not meet their criteria. They are also watching EGTX, and they have 48 notes about it, with the latest one being from September 9, 2026. They will review EGTX again on September 11 and 16, and on September 25, before the US Food and Drug Administration, or FDA, makes a decision about one of EGTX's products on September 28.

A trading run occurred on September 9 from 12:30 to 12:44 UTC, which is under the 43-minute allowance. The finish block was used for lessons and reporting from 1710 to 22. All cash was 49.14, and the own ledger had 3 closed losses with 0 open, pending, or closing. No orders were placed. Fundamentals were reviewed for stocks 1710 CHWY, 1711 ASO, 1712 SAIL, 1713 CNM, 1714 KFY, 1715 BRZE, 1716 GME, and 1717 CASY. Statistics showed a comparison between paper CHWY with a loss of 2.687668% and frozen with a loss of 1.72%. A technical feed discrepancy was noted, and a Kelly correction was applied to MC 1720, reusing data from 1682 and 1685. Consequences were evaluated in 1721. The final strategy was based on the latest title and a trading decision made at 12:30 UTC, using a query ID rather than a guess. Six monitors were resolved, including numbers 12, 15, 17, 18, 32, and 126. The 135 CHWY monitor was completed at 13:50 with an exact guide and actual open and synchronous quote. Other monitors included 136 ASO refund, 10Q, and KFY AMS and cash at 16:30, and 137 LOVE September 10 results and frozen September 9 paper exit. All branches were for research only. Jobs 67, 75, 126, and 132 were retained, and job 118 had its full output truncated to 2000 characters, replaced by 138 test with 1803 bytes. The first scheduled job 138 was pending as of 12:41, and the next run footer should be checked before claiming delivery. The previous job 118 was scheduled for 14:45, so no collection was lost before 13:50 if the worker executes a new due job. A raw SEC acceptance with Z timestamps had a conflict of around 4 hours with the issuer EDTRSS, with no earliest news minute claimed. Carryforward gaps included CHWY raising guide ranges and calls, ASO tariff refund financing of 72.224 million, KFY with no Q1 cash flow in its 10Q, GME with a net mark bridge of 37.7 million, and BRZE, SAIL, and CNM with organic acquisition effects. The AVO and PPIH overflow review was not completed, and a manual full release will occur at the next scheduled run if it is a priority, with no active position or validated entry. Artifacts are stored in local research files, including metrics.py, paper.py, and collector118_short.sh, and crucial findings were already recorded because the workspace may not persist.

A news scan found the text about Collector118 truncation repair being tested. The actual list_jobs118 last output was exactly 2000 characters and cut off at Sources/b, missing the end and overflow dates. The prior exit0 did not prove complete delivery. A replacement local research/collector118_short.sh was tested, which exits 0 with 1803 bytes and a complete end, preserving 4 RSS dates and URLs, 5 SEC panels, and 2 calendar full hashes. It omits redundant RSS title snippets and compact review footer references persisted 1299/1308. It retains a 240-minute cadence and 93 remaining runs, and create 96 extends coverage. An existing 132 actual 12:30:37 exit 0/full 1581 characters was verified, with a full footer of 1261938 and 67/75 complete. The replacement scheduling was done after a tested cancel due to a 5 job cap. This is a collection only, no trade. The next run will verify the actual new job output, not just local success.

A trading fund manager has a budget of 43 minutes starting from 12:30:45 UTC and must finish before 13:13:45 with a hard stop at 13:15:45. The manager first considers unpredictable events, specifically new earnings evidence, which includes three factors: A1, the timing of the earnings release, which is the time when the issuer first makes the information public, either through the Securities and Exchange Commission or news outlets, and when the previous preliminary information was released; A2, the quality of the cash, which can be either organic, meaning it comes from the company's operations, or acquired, and can be reported using different accounting methods, such as SBC, which stands for stock-based compensation, and GAAP, which stands for generally accepted accounting principles; and A3, any contradictions between the company's guidance and actual results, including how the market reacts and any differences between cash and realized margins. Next, the manager looks for an executable edge, which includes B1, frozen tests, meaning tests that are not currently being run, and the actual window of time, costs, and uncertainty; B2, capital, which includes the fund's own ledger, the quarter Kelly, which is a measure of the fund's risk, and risk and fund caps; and B3, execution, which includes whole shares, premarket spread, a 15-minute exit, and any gaps in the market. The manager also considers handoff, which includes C1, due monitors, meaning the sources of information that are due to be checked, and any missing details; C2, collector, which includes the actual footer, coverage, and timing; and C3, next events, such as early FDA news, earnings windows, and paper outcomes. The prior assumption is that existing rules may fail or be uncertain, and any assumption that results must be weak should be set aside. The manager starts with $49.14 in cash and aims to make a repeatable pre-event profit, with the binding constraint being an independent executable net edge. If there are three closed losses, it is not possible to estimate the average winner. There is no need to rerun failed tests unless the evidence changes the rule applicability, and new post-event strength is outside the current run-up entry. The manager should read lessons 513-515, which include notes, observations, and analyses, and verify that 1694 is the correct final prior ID.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 9, 2026, at 12:30:42 UTC. The fund manager reviewed the following SEC filings: CHWY's 10-Q filing on September 9, 2026, ASO's 8-K filing on September 9, 2026, LOVE's 8-K filing on June 15, 2026, and SFIX's 8-K filing on July 28, 2026. The manager also reviewed the following RSS feeds: SAIL's announcement on September 9, 2026, KFY's announcement on September 9, 2026, and LOVE's announcement on August 27, 2026. Additionally, the manager checked the FDA website and found information about an upcoming meeting on September 23, 2026. The manager will review the following upcoming events: new morning results on September 9, 2026, at 12:30 UTC, LOVE's results on September 10, 2026, at 12:30 UTC, SFIX's results on September 24, 2026, at 12:30 UTC, and GRAL's panel meeting on September 23, 2026, which is not an approval meeting. The manager will prioritize strong cash positions and reverify weak or early positions, but will not place any automatic orders.

The fund, which is called Catalyst Research, had a size of 0 at 10:45:17 UTC on September 9, 2026. There were several announcements from companies, including Telix, which will present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 11. Mission Produce announced its fiscal 2026 third-quarter financial results on September 8. ABM reported its fiscal third-quarter 2026 results on September 8. Roivant announced positive results from a study on September 8. The fund also reviewed filings from UNFI, DRI, PPIH, MRK, and WLTH. The websites of Kingfisher and Askul were checked and found to be working properly. The fund preserved its previous decision, known as Old52, which was made on September 8. This decision involved Roivant and its study results, as well as ABM and UNFI. The fund also considered Mission Produce and made a decision about it on September 9 at 12:30. Telix has a pending decision on September 11. The fund also reviewed macroeconomic data on September 8 and 9.

The Catalyst fund is researching IONS, MIRM, and GIS, with a size of 0, as of September 9, 2026, at 10:30:31 UTC. The fund has reviewed SEC filings for IONS on September 4, MIRM on September 8, GIS on July 1, and EAT on August 12. On September 8, Morgan Stanley maintained an overweight rating on Ionis Pharmaceuticals and lowered its price target to $104. GIS had a conference on September 8, which has already passed. The fund will review GIS's earnings on September 23. The baseline for GIS's fiscal year 2027 is an EPS of $3.00-3.20, with organic growth of -1.5 to +0.5% and savings of $750m. The fund will also review EAT's investor day on September 17 and earnings call on October 28. The fund's decisions are based on stronger or weaker organic cash flow, with no automatic entry or trade. The fund will verify full pipelines and early news for IONS, MIRM, GIS, and EAT.

The fund is called Catalyst Research and it has no size. The current time is 2026-09-09T08:45:58.513088+00:00 UTC. There are updates on the following stocks: SRRK, SCHL, and PRAX. SRRK had several announcements, including receiving FDA Fast Track Designation on September 2, 2026, presenting at upcoming investor conferences on August 27, 2026, and providing an update on global apitegromab regulatory on August 21, 2026. SCHL announced the date for its first quarter fiscal 2027 on September 3, 2026. PRAX announced inducement grants on September 3, 2026. There is also a SEC filing for SRRK on August 6, 2026. The fund will review SRRK on September 9, 12:00 UTC, September 10, 13:20 UTC, and September 29, 12:30 UTC before the PDUFA on September 30. SCHL will have a release on September 24, 16:00 ET and will be reviewed on September 25, 12:30 UTC. PRAX will replace the previous review on December 27. The fund will make decisions based on favorable or adverse data, but there will be no automatic entry and static reminders are not exact execution times. The current holdings are 3 SRRK, 1 SCHL, and 1 PRAX, with 1 SEC filing, but this is not an exhaustive list.

At 12:30 UTC, there were no proposals. The one-session rule for LOVE remains in research only. The fund had 49.14 in cash and no orders or stops. The final decision was based on the latest strategy title from the 08 UTC pre-open decision, which was verified through an ID query, not a guess. The core decision was based on time only, with a 14.8701% change and a 95% confidence interval of -1.6457 to 6.4268. There were also considerations for mandatory and target stress levels, with a -2.3414% stress level and a 0.2804% uncertain level. The largest event concentration was also a factor. The morning monitor included SAIL, CNM, and KFY, which complemented CHWY and ASO. The collector had an actual exit at 08:15:56 and was verified, with the next exit scheduled for 12:15:44. The fund retained positions in 67, 75, 118, and 126. At 12:30, the fund read the actual full releases, including organic margins, cash, acquisitions, leases, and SBC. A positive outcome would lead to a record future edge, while an adverse outcome would lead to cash, but neither would trigger an automatic buy. The calendar for September 9 included CHWY, ASO, SAIL, CNM, KFY, and SIG in the morning, and AVAV and NAVN after close. The calendar for September 10 included LOVE, MCFT, and CAL in the morning, and CPRT, ORCL, and ADBE after close. The fund added a combined monitor for September 10, but rejected a 20-cap proposal. After resolving the 126 arm, the fund preserved all other future monitors. The macro calendar included EC and QS on September 9 at 10 ET, and PPI on September 10 at 08:30 ET. The ECB had a printed statement at 14:15 CET. TLX was scheduled for September 11, but was not in a news-free window. The sources for the information were in notes 1691-1693, with small issuer and DSGX claims-time gaps named. The tests, scripts, and data were stored in /tmp/codex-run-F7wXOo, with critical events and metrics persisted observations. The lessons learned were from notes 513-515. The handoff was completed in under 20 minutes, with no capital action needed before 12:30.

A list of jobs from September 9 at 08:17 confirms that the Collector132 process ran at 08:15:56 UTC and completed successfully, producing 1569 bytes of output. This output included 4 seconds of data, 3 RSS feeds, and FDA information, and was the result of 95 runs, with 95 more runs remaining, and the next run scheduled for 12:15:44 UTC, before the 12:30 run. The same four filing dates, three RSS dates, and GRAL0 matching links and SHA4 hash ending in b945 were found as in the local test, verifying that the delivery was actually made, not just scheduled. The existing jobs with IDs 67, 75, 118, and 126 are still active, and job 126, which ran prior to 06:16, included a full EAT/GIS footer in its output, resolving a pending delivery gap from a prior run. The data sources used were https://data.sec.gov/submissions/CIK0001766502.json, https://data.sec.gov/submissions/CIK0001817358.json, https://investor.sailpoint.com/rss/news-releases.xml, and https://ir.kornferry.com/news-events/press-releases/rss. However, the timing coverage from the SEC and RSS feeds is incomplete, so it is necessary to manually check the full release from the issuer at 12:30. The replacement of job 80 with job 132 respected the limit of five active jobs.

The Catalyst fund is for research only and has a size of 0. On September 9, 2026, at 08:15:56 UTC, the fund manager reviewed the following information. The manager looked at SEC filings from CHWY on July 13, 2026, ASO on June 10, 2026, LOVE on June 15, 2026, and SFIX on July 28, 2026. The manager also reviewed news from SAIL on August 31, 2026, KFY on September 8, 2026, and LOVE on August 27, 2026. Additionally, the manager checked FDA information about a meeting on September 23, 2026, regarding GRAL, which is not an approval meeting. The manager will review new results on September 9, 2026, at 12:30 UTC, and review LOVE on September 10, 2026, at 12:30, and SFIX on September 24, 2026, at 12:30. The manager will also review GRAL on September 23, 2026. The manager will preserve cash and verify orders, with no automatic orders.

A new test of the preopen_collect.py script was completed at 08:11:41 UTC and was successful, with 1569 bytes of data collected. The test retained the LOVE and SFIX filings, as well as the LOVE RSS feed. The test also matched the expected data from the Galleri system, with a SHA hash of 4f53cda18c2baa0c0354bb5f9a3ecbe5ed12ab4d8e11ba873c2f11161202b945. The test added new filings for CHWY and ASO, and new RSS feeds for SAIL and KFY. The script was modified to output a complete hash of matching links, rather than just up to 8 links, and will require manual review if any non-zero count is detected. The script retained the existing reminders for LOVE on September 10 and SFIX on September 24, as well as the existing GRAL monitors. The script is 2798 characters long and is scheduled to run every 240 minutes, which will preserve or extend the prior 89 runs. This will provide snapshots before 12:30, but does not guarantee first-release availability due to SEC filing lag. The new job was tested and found to be ready to replace the existing collector80, which was cancelled after the test was completed. The rollback script will be kept in the original list_jobs record and a local copy of the original script will be saved in case the new script fails.

A test was run on a local command using python3 preopen_collect.py at /tmp/codex-run-F7wXOo on September 9 at 08:09:52 UTC. The test, which included 2SEC and 2RSS, was successful, with a full END footer and approximately 1.1 kilobytes of output. The test included the latest 8K filing from CHWY on July 13, the latest 10Q filing from ASO on June 10, the latest RSS from SAIL on August 31 with CrowdStrike integration, and the latest RSS from KFY on September 8 regarding a dividend. The test also included SEC submissions from https://data.sec.gov/submissions/CIK0001766502.json and CIK0001817358.json, as well as RSS feeds from https://investor.sailpoint.com/rss/news-releases.xml and https://ir.kornferry.com/news-events/press-releases/rss. The test was only monitoring metadata, and it is noted that the SEC can lag behind releases and RSS can omit earlier updates. The existing TLX and other primary collectors were retained. The script prints research-only branches and has zero size, with no order capability. The test is scheduled to run every 30 minutes through pre-open, and the actual sandbox output must be checked at 12:30, as local success does not guarantee delivery.

On September 9 at 08UTC, a test was run to check the remaining time before the morning of September 10. This test used the LOVE stock's regular session open to 15:45ET, with 15-minute intervals, and did not include overnight trading. The test reused historical data from observations 13981 to 14027, excluding previously flagged releases that were announced in advance, and making sure that any notice came before the entry. The data from 2018 to 2023 was used for training, and the data from 2024 to June 2026 was held out for diagnostic purposes. The test had one main rule, with no optimized thresholds, and considered two cost scenarios: one with a 10 basis point fee and a 10 basis point slip, and another with a 10 basis point fee and a 20 basis point slip. A stop was set at 1.5 to 2 times the prior 20-day mean range, and was checked at each 15-minute close and next bar open fill, with a final exit at 15:45. The results were compared to the SPY stock over the same time period, with an assessment of uncertainty using bootstrap and quarter Kelly methods. The test used the vectorbt library with explicit long-only and independent arithmetic, and required a command-line interface diagnostic. This test was informed by a previous study on LOVE T5, which had positive but uncertain results, so this test is not an independent validation, even though the chronological split was positive. The test aimed to determine whether late entry could plausibly work, but it cannot inherit the odds from the T5 study. No overnight order was proposed. If the necessary tests failed, the process would stop and identify any gaps in quotes or early news.

A news scan found the pre-open question tree and priors for 08:00 UTC. The budget is 42 minutes, including a final 5 minutes, and the hard start time is 08:00:40 UTC with a planned finish time of 08:42:40. Prior experience suggests setting aside a failed run-up, which means a previous attempt that did not work, does not imply that every new event will lose, but rather that it is possible for new events to be successful. The resolution, or solution, will be based on primary first-news dates, completed daily and 15-minute execution, and net cash economics, which refers to the profit or loss from a trade after considering all costs. The plan is to discard target chatter, or discussions about target prices, and repeated headlines as independent confirmation, meaning they will not be used to confirm decisions. The question tree, which is a list of questions to consider, starts with the least predictable ones: 1. Can early news invalidate calendars, which are schedules of events? 1.1. This includes FDA, or Food and Drug Administration, full pipeline: 1.1.1 early approval or CRL, which stands for Complete Response Letter, versus goal date; 1.1.2 overlapping trial or financing. 1.2. Earnings, which are a company's profits: 1.2.1 preliminary versus complete; 1.2.2 call, or a meeting to discuss earnings, versus first release. 2. Is next-two-session coverage complete enough? 2.1. Domestic, or US, coverage: 2.1.1 Sep 9 before and after; 2.1.2 Sep 10 before and after. 2.2. Outer markets, which are markets outside the US: 2.2.1 Inditex, a European company, and European morning; 2.2.2 dated crypto events, which are events related to cryptocurrency, and venue eligibility. 2.3. Macro structure, which refers to the overall economic environment: 2.3.1 ECEC, or European Central Bank's economic indicators, versus ECI, or Employment Cost Index, PPI, or Producer Price Index, and CPI, or Consumer Price Index; 2.3.2 holiday-delayed oil and claims. 3. Could a trade earn positive net cash? 3.1. Evidence: 3.1.1 frozen holdout odds, which refer to the probability of a trade being successful; 3.1.2 correlated sample and selection. 3.2. Economics: 3.2.1 organic demand, which refers to demand that is not influenced by external factors, versus financial marks, which are prices set by financial markets; 3.2.2 cash after capex, or capital expenditures, and SBC, or stock-based compensation. 3.3. Execution: 3.3.1 $49.14 whole-share capacity, which refers to the maximum amount of shares that can be traded; 3.3.2 15-minute stops, which are limits on the amount of time a trade can be open, cannot bound gaps, which are large price movements. 4. What survives until 12:30? 4.1. Controls: 4.1.1 due own monitors, which are systems that track and control trades; 4.1.2 actual collector footer, which is a summary of trade data, and truncation, which refers to the process of cutting off or limiting trade data. 4.2. Decision reversal: 4.2.1 independent positive net actual-window edge, which refers to the ability to make a profit from a trade; 4.2.2 adverse or date change updates without automatic trade. The start cash is $49.14, and the goal is to repeat pre-event gains, with a binding constraint, which is a limit that must be followed, calibrated edge, which refers to the ability to make a profit from a trade. There is no authorization to execute orders, and the CIO, or Chief Investment Officer, receives proposals.

The fund manager of the Catalyst fund made some research notes. The notes are for research only and are not approved. The manager compared some links to prior notes. On September 9, 2026, at 07:30:32 UTC, the manager checked a website, https://www.fda.gov/, and found no matching links. The manager also checked the SEC filings for SFIX on July 28, 2026, and LOVE on June 15, 2026. Additionally, the manager checked an RSS feed from LOVE on August 27, 2026, about a conference call. The manager made a note to review LOVE on September 10 at 12:30 UTC and SFIX on September 24 at 12:30 UTC. The manager will monitor the companies' growth and cash flow, and will not make any automatic orders. The manager will also verify the primary date if there are any adverse events.

The Catalyst Research fund has the following updates: Telix completed enrollment in a Phase 3 study on September 1, 2026. Mission Produce announced its fiscal 2026 third-quarter financial results on September 8, 2026. ABM reported its fiscal third-quarter 2026 results on September 8, 2026. Roivant announced positive results from a study on September 8, 2026. The fund also reviewed SEC filings from UNFI, DRI, PPIH, MRK, and WLTH. Additionally, the fund checked the websites of Kingfisher and Askul. The fund made decisions on ROIV, ABM, UNFI, AVO, and TLX, including choosing AVO on September 9 at 12:30 UTC. The fund also reviewed macroeconomic data on September 8 and 9.

The fund manager of the Catalyst fund is researching IONS, MIRM, and GIS, with a size of 0, as of September 9, 2026, at 06:16:02 UTC. The manager has reviewed SEC filings for IONS on September 4, 2026, MIRM on September 8, 2026, GIS on July 1, 2026, and EAT on August 12, 2026. On September 8, 2026, Morgan Stanley maintained an overweight rating on Ionis Pharmaceuticals and lowered its price target to $104. GIS had a conference on September 8, 2026, at 19:00 UTC, which has already passed. The manager will review earnings for GIS on September 23, 2026, at 13:00 UTC. The manager will also review earnings for EAT on October 28, 2026, at 16:30 UTC. The manager has chosen to review EAT's investor day on September 17, 2026, at 16:30 UTC. The manager will verify full pipelines and early news for IONS, MIRM, GIS, and EAT.

A news scan found the headline of a report from an automated trading fund manager. The report states that at 06UTC, the system ran for about 15 minutes and had $49.14 in cash with no orders. The main restaurant stock, referred to as T5 or T1, had a holdout of -13.0727%, which is a measure of how well the system performed on unseen data. The system also reported a mean of -2.0993%, which is a measure of average performance, and a quarter Kelly of 0, which is a measure of the optimal fraction of the portfolio to invest. The stress of the system was -15.3732%, which is a measure of the system's risk. The system also reported on the performance of specific stocks, including TXRH, which was up 3.2141%, and EAT and CBRL, which were down 19.2065% and 23.2256%, respectively. The statistical analysis of the system's performance showed that the quarter block confidence interval was [-3.792, -0.302]%, which is a measure of the range of possible performance. The indicators all showed negative holdout means, which is a measure of how well the system performed on unseen data. The Monte Carlo analysis, which is a method of simulating random outcomes, showed that the positive allocations had a loss of about 94% conditional on certain events. The system also reported on the fundamental analysis of EAT, which showed a positive free cash flow of $557.5 million, up 34.76%, but no entry edge, which is a measure of the potential for profit. The system retained cash and had no proposals. The report also mentioned that there were no changes to the system's parameters, including the 67, 75, 80, and 118, which are likely parameters of the system's models. The report concluded with no action before 08UTC and no proposals.

The trading fund manager accepted vectorbt 1551-54 directions for long-only trades. A textual typo was corrected, changing 'each 8 symbol/cost/split portfolio' to the actual 3 symbols, 2 splits, and 2 costs, which equals 12 per-symbol reconciliations, plus 4 pooled summaries. This correction did not change any numerical results. There were 56 quarterly events, consisting of 19 TXRH, 19 EAT, and 18 CBRL events, with 36 used for training and 20 held out. An initial SEC metadata scan of 56 items and 2.02 filings included 2 CBRL updates and missed 2 EAT 2023 earnings filed only on 9.01, but these were repaired before price outcomes were determined. CBRL updates on May 16 and November 14, 2024, preceded full releases on May 30 and December 4, 2024, and flags were retained without affecting holdout outcome selection. All 56 release dates were equal to the filing date in this final sample, but 12 report date differences demonstrate that report dates are not reliable. The dataset includes daily 1259 bars for each of the 4 symbols, with 20 intraday windows and 2937 bars, and all entry opens match daily opens, while 17 closing aggregates differ by a maximum of 26.40%. Time exits use daily close, not the last 15-minute proxy. Local artifacts and scripts are stored in /tmp/codex-run-mYxPx3, and observations hold all critical numbers in case the filesystem is lost. The sample is conditional on the retrospective actual release calendar, and advance-notice coverage is incomplete, with no historical bid-ask data, so there is no claim of trade-ready out-of-sample deployment. Replacement 126 active and actual sandbox output are pending, while existing 67, 75, 80, and 118, and 20 monitors are retained.

A news scan found the headline about the 06UTC collector48 replacement being tested. The primary EAT dates and capacity gap were reviewed. The 20armedmonitor cap rejected the newEATSep17researchreview because it had 422 too many monitors. The existing 20 monitors remain unchanged. Local scripts, specifically the collector.sh script, were tested with 4 SEC symbols, including IONS, MIRM, GIS, and EAT, with 1 discovery and 2 GIS and 2 EAT reminders, and it exited with a code of 0 and 1941 bytes, indicating a successful test. The replacement of the 48 collector with a new one that runs 96 times with a timeout of 45 minutes will preserve the existing checks and compact the GIS past Sep 8 source reference points to the original 48 note, which can be found at https://investors.generalmills.com/press-releases/press-release-details/2026/General-Mills-to-Webcast-Remarks-at-Barclays-Global-Consumer-Staples-Conference-on-Sept--8-2026/default.aspx. A new EAT issuer was announced on Aug 31 for Sep 17 from 08:30 to 11:15 CT for an investor day, which can be found at https://investors.brinker.com/news/news-details/2026/BRINKER-INTERNATIONAL-TO-HOST-INVESTOR-DAY-ON-SEPTEMBER-17/default.aspx, and a review was chosen for Sep 17 at 16:30 UTC. Another issuer was announced on Aug 12, which can be found at https://www.sec.gov/Archives/edgar/data/703351/000070335126000026/fy26q4ex991-earningsrelease.htm, with a forward calendar of Oct 28 for an earnings call, and a review was chosen for Oct 28 at 16:30 UTC, with a re-verification of the primary announcement before the window. Both branches have stronger organic cash, which is a measure of a company's cash flow, and record or independent validation, but weak or absent cash requires re-verification. Neither is an automatic entry, and the earnings rule 1553 holdout of 19.2065% N7 cannot calibrate the investor day. Static reminders are not armed monitors. No new CBRL future date was found, and the Sept 2025 date or vendor 2026 estimate should not be imported. These dates require no capital action before 08 UTC. The replacement's first sandbox output is pending until the actual run.

A news scan found the preregistration report for a restaurant earnings transfer test. The test starts at 06:00:29 UTC and is planned to last 39 minutes, with a hard stop at 45 minutes and 5 minutes reserved at the end. The report notes that prior results, such as those from DRI, may be due to luck or common restaurant earnings anticipation. The test has a three-level question tree: Identification, which includes the event clock and population; Payoff, which includes the frozen window and transfer; and Mechanism, which includes regimes and execution. The test also considers Generalization, which includes economics and sizing. There are at least 24 leaf questions. The report states that the fixed rule is to buy the fifth SPY session strictly before the earnings actual date and sell the last session before, with no hold through. The report uses SEC item 2.02 exhibits to establish retrospective actual dates and flags missing advance notices and other news. The training period is 2022-24 and the holdout period is 2025-2026 Sep 8. Fees are 10 basis points and slippage is 10 basis points each side, with stress slippage at 30 basis points. The baseline is all events, and diagnostic groups include unoptimized prior SMA50, prior 20 momentum, and SPY 50 groups. The report notes that no new positions will be taken unless independent net edge and execution are proven, and new symbols are chosen by business type, not prior returns.

The Catalyst fund is focused on research for IONS, MIRM, and GIS, with a size of 0. On September 9, 2026, at 04:45:14 UTC, the fund manager reviewed the following filings: IONS filed with the SEC on September 4, 2026, MIRM filed with the SEC on September 8, 2026, and GIS filed with the SEC on July 1, 2026. A news scan found the headline that Morgan Stanley maintained an overweight rating on Ionis Pharmaceuticals and lowered its price target to $104 on September 8, 2026. The fund manager also noted two upcoming events for GIS: a conference on September 8, 2026, and earnings on September 23, 2026. The manager will review the company's organic volume and cash flow, as well as any new guidance, to decide whether to retain cash or seek new opportunities. The baseline for GIS is an EPS of $3.00-3.20 for FY27, with organic growth of -1.5% to +0.5% and savings of $750 million. The fund manager will verify the full biotech pipelines and early decisions, but will not make any automatic trades.

The Catalyst Research fund made notes on September 9, 2026, at 04:45:14 UTC. The fund looked at SEC filings from HITI on August 31, 2026, and BFRI on August 13, 2026. It also noted that Dave & Buster's Entertainment, Inc., ticker symbol PLAY, will report its second-quarter results on September 1, 2026. The fund has a list of static reviews, which are not guaranteed to be released or delivered on time, including TSM on September 10, DATA.L on September 14, and others. It also has a list of new reviews, including CAN on September 8 and PLAY on September 15. The fund uses a strategy of recording organic cash and credible clinical evidence, and staying in cash if there are adverse or delayed results. It rejected a trade for PLAY with a 13.15% return and a confidence interval of -4.48% to 7.25%. The fund also made an early decision on EGTX, which is not bounded by a stop. The fund has 48 notes on EGTX with a hash of 85e339a790c3 and a latest update on September 2026. It will review EGTX on September 11 and 16, and again on September 25 before the FDA decision on September 28. If there is a new label, PRV, or cash, the fund will record and validate it, and if there are adverse or delayed results, it will stay in cash and reverify.